Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Advicenne
Deal Size : Undisclosed
Deal Type : Partnership
Avanzanite Bioscience Expands Partnership with Advicenne in Additional European Countries
Details : Under the partnership, Avanzanite gains commercialization and distribution rights into three additional European countries, for Sibnayal (potassium citrate and potassium bicarbonate), the first approved medicinal product in Europe for distal Renal Tubula...
Brand Name : Sibnayal
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 18, 2023
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Advicenne
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Advicenne
Deal Size : Undisclosed
Deal Type : Agreement
Details : Sibnayal (potassium citrate) is a medicine used to treat patients from the age of one year with distal renal tubular acidosis (dRTA), a disease in which the kidneys do not remove acid through the urine well enough.
Brand Name : Sibnayal
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 28, 2023
Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Advicenne
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : SIFI
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Sifi Announces License Agreement with Avanzanite Bioscience for Akantior®
Details : AKANTIOR® (polihexanide) is an investigational anti-amoebic polymer that has been granted Orphan Drug Designation by both the European Medicines Agency ("EMA") and Food and Drug Administration ("FDA") for AK.
Brand Name : Akantior
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 10, 2023
Lead Product(s) : Polyhexanide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : SIFI
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?